NCT01161264View on ClinicalTrials.gov

Safety and Immunogenicity of Influenza Vaccine (Surface Antigen, Inactivated) Ph.Eur, Formulation 2010/2011, When Administered to Adult and Elderly Subjects

PHASE3CompletedINTERVENTIONAL
Enrollment

126

Participants

Timeline

Start Date

July 31, 2010

Primary Completion Date

July 31, 2010

Study Completion Date

July 31, 2010

Conditions
Seasonal Influenza
Interventions
BIOLOGICAL

Influenza Vaccine (Surface Antigen, Inactivated) Ph.Eur, Formulation 2010/2011

Single 0.5 mL dose administered into the deltoid muscle of (preferably) the non-dominant arm on Day 1.

Trial Locations (1)

Unknown

Novartis Investigational Site, Germany

Sponsors

Lead Sponsor

Novartis Vaccines
All Listed Sponsors
lead

Novartis Vaccines

INDUSTRY

NCT01161264 - Safety and Immunogenicity of Influenza Vaccine (Surface Antigen, Inactivated) Ph.Eur, Formulation 2010/2011, When Administered to Adult and Elderly Subjects | Biotech Hunter | Biotech Hunter